Anergis Initiates Development of Second-Generation COP Allergy Vaccines; Announces Publication of Sustained Efficacy Data from Ph. IIb Study Follow-up
- 2-month treatment with AllerT COP allergy vaccine provides sustained clinical benefit for more than one pollen season
- Research program to develop next-generation COP allergy vaccines in progress
EPALINGES, Switzerland, September 5th, 2018 – Anergis, a company developing proprietary ultra-fast Allergy Immunotherapy (AIT), announced today that the Company has initiated the development of the second generation of its ultra-fast COP allergy vaccines. Moreover, the Company reported the publication of key proof-of-concept data from a clinical phase IIb follow-up trial demonstrating sustained clinical efficacy of its birch pollen vaccine AllerT for more than one pollen season.
In 2016, results of a Phase IIb trial with the AllerT COP allergy vaccine published in the Journal of Allergy and Clinical Immunology  demonstrated the efficacy of AllerT during the natural birch pollen season immediately following a single 2-month treatment course. The new data published in this year's August issue of the Journal of Allergy and Clinical Immunology  demonstrate that the efficacy of AllerT persisted during the following annual pollen season a year later without repeated treatment. Results were based on a follow-up including 196 of 240 patients that originally enrolled in the study.
Improvements in scores after the second season for both primary and secondary endpoints were over 20%, the threshold usually considered to be clinically relevant. Together with earlier evidence of immunological memory lasting for at least 4 years , these clinical data confirm the core concept of ultra-fast AIT, i.e. eliciting a persistent benefit by administering a single treatment course with a COP allergy vaccine.
For optimized clinical efficacy and tolerability, Anergis now has initiated a new preclinical research program to design the next generation of COP allergy vaccines. Second-generation COP allergy vaccines are designed to boost and at the same time to modulate the immunogenicity of COPs towards a more TH1 rather than TH2 immune response. As part of this program, Anergis has entered into a research collaboration with Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines.
Research to identify the most suitable formulation has already started, with initial results expected in Q1/2019. Subsequently, Anergis aims to proceed to the clinical evaluation of its second-generation COP allergy vaccines as soon as possible.
 Spertini et al. JACI 2016 “Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study” 138;1:162-168
 Kettner et al. JACI 2018 “Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season” 142;2:678-680.e7
 Spertini et al. JACI 2014 “Safety and immunogenicity of immunotherapy with Bet v 1–derived contiguous overlapping peptides” 134;1:239-240.e13